Smith & Nephew PLC reported a revenue of $1,412 million for Q3 2024, up 4.0% from $1,357 million in Q3 2023, impacted by challenges in the Chinese market but showing overall growth in orthopaedics and advanced wound management. The company expects a full-year revenue growth of approximately 4.5%, revised from a previous estimate of 5.0% to 6.0% due to ongoing headwinds.